Starpharma (ASX:SPL) Releases FY25 Financial Results
Financial Performance
Starpharma reported FY25 revenue of $4.9 million, a 183% increase compared to FY24’s $1.7 million, excluding the $6.6 million one-time settlement payment from Mundipharma for VivaGel BV. The revenue growth was driven by research revenue from Petalion Therapeutics and increased sales of Viraleze and VivaGel BV.
The company ended the financial year with a cash balance of $15.4 million and anticipates an R&D tax incentive refund of $3.7 million in H1 FY26. Starpharma reported a loss of $10.0 million for FY25, a 31% improvement over the prior year’s loss of $14.7 million, excluding the Mundipharma settlement. The reduced loss includes lower research and product development expenditure, which amounted to $8.4 million net of the Australian Government’s R&D tax incentive.
Investor Hub
Starpharma encourages shareholders to visit its new Investor Hub, offering access to company developments and strategic insights. Investors can watch a video with CEO Cheryl Maley discussing key highlights from the 2025 Annual Report.
Motley Fool contributor Kiarra Jackson has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
